Dr Frankel discusses the clinical benefits of SGLT2 inhibitors, the potential risk of euglycaemic diabetic ketoacidosis and how to manage their prescribing in both chronic kidney disease and acute kidney injury.
Medication safety shorts
Parkinson's time critical medication
Vasopressin deficiency: the importance of desmopressin
The impact of steroids on diabetes control